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Purpose: The objective of this study is to evaluate toxicity and cosmetic outcome in breast cancer patients treated
with adjuvant hypo fractionated radiotherapy to the whole breast, and to identify the risk factors for toxicity.
Methods and materials: Two hundred twelve women with early breast cancer underwent conserving surgery
were enrolled in the study. The patients received 40.05 Gy in 15 daily fractions, 2.67 Gy per fraction. The boost to
the tumor bed was administered with a total dose of 9 Gy in 3 consecutive fractions in 55 women. Physician-rated
acute and late toxicity and cosmetic outcome (both subjective and objective) were prospectively assessed during
and after radiotherapy.
Results: In our population study the mean age was 63 with the 17% (36 pts) of the women younger than 50 years.
The median follow-up was 34 months. By the end of RT, 35 patients out of 212 (16%) no acute toxicity, according
to the RTOG criteria, while 145 (68%) and 31 patients (15%) developed grade 1 and grade 2 acute skin toxicity,
respectively.
Late skin toxicity evaluation was available for all 212 patients with a minimum follow up of 8 months. The
distribution of toxicity was: 39 pts (18%) with grade 1 and 2 pts (1%) with grade 2. No worse late skin toxicity was
observed.
Late subcutaneous grade 0-1 toxicity was recorded in 208 patients (98%) and grade 2 toxicity in 3 patients (2%),
while grade 3 was observed in 1 patient only. At last follow up, a subjective and objective good or excellent
cosmetic outcome was reported in 93% and 92% of the women, respectively. At univariate and multivariate analysis,
the late skin toxicity was correlated with the additional boost delivery (p=0.007 and p=0.023). Regarding the late
subcutaneous tissue, a correlation with diabetes was found (p=0.0283).
Conclusion: These results confirm the feasibility and safety of the hypofractionated radiotherapy in patients with
early breast cancer. In our population the boost administration was resulted to be a significant adverse prognostic
factor for acute and late toxicity. Long-term follow up is need to confirm this finding.Introduction
The radiation therapy represents the standard adjuvant
treatment for the early-stage breast cancer after breast
conserving surgery (BCS), in order to maximize local
control and overall survival [1]. Adjuvant radiotherapy
has been shown to improve local control and overall* Correspondence: patrizia.ciammella@asmn.re.it
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article, unless otherwise stated.survival, with a 70% reduction in the risk of recurrence
[2,3] and a 9-12% reduction in the risk of death [4-6].
The most widely used fractionation regimen is 1.8 to 2-
Gy daily fractions for a total dose of 45 to 50 Gy to the
whole breast over 5 weeks with or without a boost to
the surgical bed.
Although there has been concern that the whole-
breast radiotherapy using daily dose > 2 Gy/fraction
might increase late toxicity and impair cosmesis in BCS
patients [7], over the last years, there has been renewed
interest in hypofractionated whole breast irradiationtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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over a shorter time period. HF-WBI is associated with
reduction in the length of treatment by 2-3 weeks com-
pared to conventional schedules that require 6-7 weeks.
This approach have important practical advantages and
biological implications. Their convenience, also in terms
of cost savings to the patient and the health care pro-
vider, may facilitate patient acceptance and compliance
with radiotherapy. Large multicenter randomized trials
with 5- to 10-year follow-up data have shown efficacy
and safety in terms of local control and cosmetic out-
come [8,9], however, only few studies have investigated
cosmesis [10-12] and quality of life [11]. The first rando-
mised trial was conducted in Canada and has tested
42.5 Gy in 16 fractions against 50 Gy in 25 fractions,
resulting in equivalent local control and breast cosmesis
[13]. The two most recent randomized studies, con-
ducted in UK (START Trials), have demonstrated that
the hypofractionation offers a favourable rates of late ef-
fects and loco-regional tumor control [8,13]. Because of
the greater risk of worse fibrosis and skin toxicity, several
studies hypo fractionation excluded the large-breasted
women [8]; some other trials included these patients but
without providing clear information about the impact of
breast volume on toxicity and cosmesis [10,13].
The aim of the present prospective study is to assess
the acute and late toxicity and the cosmetic outcome of
a postoperative HF-WBI for early breast cancer, and to
analyze their correlation with clinical and dosimetric
characteristics.
Methods and materials
Characteristics of patients and data collection
From January 2009 and December 2012, two hundred
twelve women with early breast cancer were recruited
in this mono-institutional prospective trial of HF-WBI.
The inclusion criteria were: age ≥ 18 years, histological
proven unilateral early-breast cancer, prior conservative
surgery (lumpectomy or quadrantectomy), pathological
stage pT1-pT2, pN0-1 according to American Joint
Committee-Union Internationale Contre le Cancer sta-
ging system (AJCC-UICC, 6th edition), negative surgical
margins. All patients provided an informed consent. Pa-
tients previously irradiated on the controlateral breast,
with synchronous bilateral breast cancer, with > 4 posi-
tive lymph nodes, connective tissue disorders were ex-
cluded from the present study.
The diabetes mellitus and the chemotherapy were not
considered factors of exclusion and indeed were ana-
lyzed as independent factors for toxicity. Our Institu-
tional Ethic Committee approved this study. Adjuvant
systemic therapy was prescribed after multidisciplinary
evaluation and was mostly based on the most recent San
Gallen Expert Meeting Consensus.Radiation treatment
The planning CT scan (5 mm slice thickness) from the
level of the larynx to the upper abdomen were obtained
in the supine position using “wing-board” or other per-
sonalized immobilization device with both arms raised
above the head. The Clinical Target Volume (CTV) in-
cluded whole breast tissue and was expanded by 5 mm
to create the Planning Target Volume (PTV). Organs at
risk (OARs), lungs and heart, were contoured.
A three dimensional conformal radiotherapy, planned
with Eclipse Varian, was calculated both for whole breast
and boost irradiation. Whole breast was treated to a
total dose of 40.05 Gy in 15 consecutive daily fractions,
2.67 Gy per fraction. An additional dose of 9 Gy in three
consecutive fractions was delivered in patients with risk
factors for local relapse (age < 50 years or close surgical
margins). The dose was prescribed to the ICRU refer-
ence point, according with the following constraints:
95% and 90% of the prescribed dose to the 95% and the
90% of the PTV respectively. For each patient, dose-
volume histograms (DVHs) for the target and OARs
were obtained.
Follow-up, toxicity and cosmesis assessment
All patients underwent clinical examination before ir-
radiation, weekly during the treatment course and every
three months for the first year and then every six
months. Surveillance for disease recurrence included a
clinical examination at every time point, and mammog-
raphy once a year. Acute skin toxicity was assessed dur-
ing and at the completion of RT and after 3 months; late
effects and cosmetic outcome were evaluated at each
clinical visit.
Late skin and subcutaneous toxicity were evaluated in
accordance with the RTOG grading schema [14,15]. For
all patients the cosmetic outcome was evaluated by pa-
tient (subjective score) and physician (objective score).
The cosmetic assessment was performed by the phys-
ician using the contralateral, untreated breast as the ref-
erence. The cosmetic outcome was scored using the
Harvard scale [16]. An excellent cosmetic result score
was assigned when the treated breast looked like essen-
tially the same as the contra lateral one (as it relates to
radiation effects). A good cosmetic score was assigned
for minimal but identifiable radiation effects of the
treated breast. A fair score meant that significant radi-
ation effects were readily observable. A poor score was
used for severe sequelae of breast tissue secondary to ra-
diation effects.
A patient-based cosmetic evaluation was done accord-
ing to the standard European Organization for Research
and Treatment of Cancer (EORTC) Breast Cancer Rat-
ing System for Cosmetic Results of Breast Conserving
Treatment. In brief, they were asked to compare their
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following items: breast size and shape, location and shape
of areola/nipple, skin color, breast edema, appearance of
surgical scar, telangiectasia, and global cosmetic result.
Items were graded on the following four-point scale: no
difference or excellent, small difference or good; moderate
difference or fair, and large difference or poor.
The patients (age, comorbidities, body mass index) and
medical treatments (neoadjuvant/adjuvant chemotherapy,
hormonal deprivation, other concomitant drugs) character-
istics were analyzed and correlated with toxicity and cos-
metic outcome. Furthermore, we analyzed the impact of
the CTV volume (representing the breast size), and the
dosimetric data, with special focus on the maximum dose
and dose in homogeneity (defined as the absolute volumes
of breast tissues exposed to ≥100%, ≥104% and ≥107% of
the prescribed).
Statistical analysis
The χ2 and Mann–Whitney tests were used to compare
acute skin toxicity and late skin and subcutaneous toxicity
between different sample groups and to analyze associa-
tions between toxicity and cosmetic outcome with clinical
characteristics. Multivariate analysis to independently pre-
dict the risk of skin and subcutaneous toxicity development
was performed using binary logistic regression. The abso-
lute breast volumes receiving >100%, >104% and >107% of
the prescribed doses (40.05 Gy and 49.05 Gy for patient re-
ceiving an adding boost respectively) were summarized and
correlated with the subcutaneous toxicity. For each dose
level, medians were used to split the distribution into two
groups for the analysis: <median and <median. Multiple lo-
gistic regression was used to test the association between
breast volume receiving different levels of prescribed dose
and late subcutaneous toxicity for whole breast and boost
treatment schedules.
Statistical significance was assumed at p < 0.05; data
were processed using the R Package Version 2.15.
Results
The mean age was 63 (range 39-88 yrs) with the 17% of
the women younger than 50 years. Twenty three (11%)
and twenty five (12%) patients were affected by diabetes
mellitus and hypertension, respectively. 15% had tumors
with a diameter ≥ 2 cm; 12% had hormone-receptor–
negative disease and 26% had poorly differentiated
disease. All patients received prior breast conserving
surgery (no tumorectomy). In this study, 24 patients had
close margins (within 2 mm from the surgical margin
but not tumor on ink) at final pathological examination.
Thirty four patients underwent level I/II axillary lymph-
nodes dissection and 165 sentinel node biopsy alone.
The most common site was supero-externe quadrant
(103, 48%) followed by supero-central (38, 18%) andlower outer quadrant (17, 8%). One hundred fourthy six
patients (64%) had T1 tumors 32 patients (15%) had T2
tumors, 41 (19%) had in situ tumor. Invasive ductal car-
cinoma was the commonest pathological type (152, 72%)
while invasive lobular carcinoma was found in only 17
patients (8%). Neo-adjuvant chemotherapy was adminis-
tered in 10 patients; 34 patients received adjuvant
chemotherapy and 170 hormone therapy. The chemo-
therapy regimens were antracycline-based (± taxanes).
Eighteen patients (8%) underwent trastuzumab therapy.
Patients characteristics and details of treatments are
shown in Tables 1 and 2.
Median time from surgery to RT was 65 days with
overall median radiation treatment duration of 22 days.
No patient interrupted the treatment.
The median follow-up was 34 months (range 8-
44 months). At last follow up all patients are alive with-
out local recurrence.
The median breast volume was 760.64 cc (range 44.77-
1892.1 cc). The median boost volume was 143.33 cc (range
23.07-230.02 cc). The median breast volume for each iso-
dose group >100%, >104% and >107% were 562 cc (range
79.7-1520.7 cc), 216.6 cc (range 13.1-905 cc) and 13.6 cc
(range 0-549.8 cc), respectively.
Acute toxicity
For simplicity, patients were considered to have mild
skin reaction for those with G1, moderate skin reaction
for those with G2, and severe skin toxicity for those with
G3-G4 reaction. The overall frequency of acute toxicity
was reported in Table 3. Mild acute skin toxicity was ob-
served in 168 patients (79%); 12% of patients developed
moderated skin toxicity and only one patient, affected by
diabetes mellitus and obesity, experienced a grade 3 re-
action. The remaining 39 patients (18%) showed no
acute toxicity. Neither skin ulceration nor soft tissue ne-
crosis (grade 4 toxicity) was observed. Distribution of
Acute Skin Toxicity (AST), Late Skin Toxicity (LST)
and Late Subcutaneous Toxicity (LSCT) according to
RTOG scale was shown in Figure 1.
Median delay between RT initiating and first skin reac-
tion was 12 days (range: 5-40 days). Median dose to first
skin reaction was 29.37 Gy (range 13.35-40.05 Gy). No
treatment disruption was necessary.
Patient and treatment related factors have been evalu-
ated in a univariate analysis (Table 4). At Mann-Whitney
test only the boost administration was found to be statis-
tically significant as concerns the occurrence of acute
skin reaction (p = 0.001156). In our analysis other clin-
ical factors such as age, smoking, hypertension and
chemotherapy were not correlated with the development
of acute skin reaction.
A significant correlation by Binary logistic regression test
between breast volume [p = 0.01504, Odds Ratio, OR 2.4738
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0.9909 (0.98363-0.9982)] and surgical outcomes [p =
0.00383, OR 3.4577 (1.4914-8.0161)] was found for the oc-
currence of acute toxicity. Analyzing separately the “no
boost” group, the only and unexpected variable retaining
significance was the surgical deficits [p = 0.00061, OR
7.665326 (2.405551-24.42568)].
Results from the multivariate analysis suggested that
after adjusting for breast size, boost administration and
surgical deficits, there was no evidence that the risk of
acute skin effects of radiotherapy was associated with
dose inhomogeneity.Table 2 Treatment and dosimetric characteristics
Breast Volume
Average cc 813.8
(Range) (89.6 - 1892.1)
Boost Total patients 55 (26%)
Boost Volume
Average cc 138.75




Mean Maximum Dose (Gy) 43.65
Breast volume riceiving ≥ 100% dose (cc)
(Range) 79.7 - 1520.7
Breast volume receiving ≥ 104% dose (cc)
(Range) 13.1 - 905
Breast volume receiving ≥ 107% dose (cc)
(Range) 0 - 549.8
Table 3 Frequency of any grade of acute skin toxicity
RTOG Total patients





Table 4 Univariate and multivariate analysis: predictive
factors for acute skin radiation – induced toxicity
Variables Univariate analysis Multivariate analysis




Breast volume 0.696 = 0.01504 [OR 1.00612
(0.99659 – 1.01588)]
Diabetes 0.149 0.568
Surgical deficits 0.107 = 0.00383 [OR 3.4577
(1.4914 – 8.0161)]
Boost administration = 0.0001156 = 0.00543 [OR 0.9909
(0.98363 – 0.9982)]
V > 100% - 0.608
V > 104% - 0.323
V > 107% - 0.279
Boost V > 100% - 0.997
Boost V > 104% - 0.997
Boost V > 107% - 0.546
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Late toxicity was assessed at 6 months from the end of
radiotherapy and thereafter. The frequencies of late skin
and subcutaneous toxicity was reported in Tables 5 and 6.
Late G1 skin toxicity, scored with RTOG scale, was
observed in 39 patients (18%); only 2 patients showed
G2 late skin reactions. No late skin toxicity > grade 2
was observed. At univariate analysis, as summarized in
Table 7 only the boost administration was related to late
skin toxicity (p = 0.0007174). This correlation was also
confirmed by the multivariate analysis [p = 0.019, OR
3.056 (1.280-7.297)]. There was a higher but not statisti-
cally significant incidence of late skin toxicity in the pa-
tients who developed early skin reaction (p = 0.2183).
Late subcutaneous G0-G1 toxicity was recorded in 98%
of patients; G2 toxicity was observed in 2% of patients and
only in 1 patient showed G3 toxicity. At Mann-Whitney
test only the diabetes was found to be statistically signifi-
cant as concerns the occurrence of late subcutaneous tox-
icity (p = 0.0283), while at multivariate analysis the only and
unexpected variable retaining significance was the chemo-
therapy administration [p = 0.0184, OR 2.5923 (1.1745-
5.7217)] (Table 8). With regard to the dosimetric factors,
both the V104 [p = 0.00864, OR 0.07604728 (0.01122575-
0.5151717)] and V107 [p = 0.02045, OR 6.268894 (1.338293-
29.36504)] were found to be related to the chronic subcuta-
neous toxicity. Analyzing the “no boost” group, the only
variable correlated with late subcutaneous toxicity was the
diabetes [p = 0.00350, OR 3.514025 (1.092603-11.30179)].Figure 1 Distribution of acute skin toxicity (AST), late skin
toxicity (LST) and late subcutaneous toxicity (LSCT).Cosmetic outcome
Cosmetic results were assessed and scored at the end of
RT and then every 6 months. The distribution of object-
ive and subjective cosmetic outcome was showed in
Figure 2.
At last follow up, 197 women (93%) declared a sub-
jective good or excellent cosmetic outcome; the objective
score, recorded by physician, was good or excellent in
196 (92%) patients. Fifteen patients (7%) got unsatisfac-
tory subjective cosmetic results (fair in 12 cases and
poor in 3). The physician reported a poor outcome only
in two patients and fair results in 14.
Figure 3 shows an examples of excellent (A), good (B),
fair (C) and poor (D) cosmetic results. The univariate ana-
lysis of the subjective results showed that diabetes was cor-
related with a poor outcome (p = 0.02377); this result was
confirmed also with the multivariate analysis [p = 0.0596,
OR 0.2767931 (0.07273-1.053304)]. With regard to cos-
metic outcomes assessed by physicians, the binary logistic
regression showed that age [p = 0.003141, OR 0.8985
(0.8370-0.9647)], chemotherapy administration [p = 0.0409,
OR 0.108474 (0.02440211-0.482173)] and breast volumeTable 5 Frequency of any grade of late skin toxicity
RTOG Total patients





Table 6 Frequency of any grade of late subcutaneous
toxicity
RTOG Total patients





Table 8 Univariate and multivariate analysis predictive
factors for late radiation induced subcutaneous toxicity
Variables Univariate analysis Multivariate analysis
p value p value [OR]




Breast volume 0.694 0.483
Diabetes = 0.0283 0.055
Surgical deficits 0.854 0.499
Boost administration 0.5157 0.298
V > 100% - 0.745
V > 104% - = 0.00864 [OR 0.07605
(0.01122 – 0.51517)]
V > 107% - = 0.02045 [OR 6.26889
(1.33829 – 29.36504)]
Boost V > 100% - 0.728
Boost V > 104% - 0.099
Boost V > 107% - 0.585
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correlated with fair-poor results.
Discussion
The delivery of daily doses higher than 1.8-2 Gy with
hypofractionated schedule is a widespread option to per-
form whole breast irradiation after breast-conserving
surgery for early-breast cancer [17]. The HF-WBI has
been used in several institutions for decades and tested
in randomized trials [18,19]. There are three randomized
trials performed in the last years that have compared
hypofractionation with conventional radiotherapy for
whole breast irradiation. In the Canadian trial 1,234
women with early-breast cancer were randomized after
breast conserving surgery to accelerated HF-WBI
(42.5 Gy/16 fx) or standard course (50 Gy/25 fx). This
study demonstrated with a median follow up of 12 years
a comparable results between two groups of patients in
terms of local control and adverse events [20]. The UK
standardization of breast radiotherapy (START) Trial A
enrolled 2.236 patients randomized to conventional radi-
ation therapy versus two different schedules of hypofrac-
tionation (41.6 or 39 Gy in 13 fractions) [13]. In theTable 7 Univariate and multivariate analysis predictive
factors for late radiation induced skin toxicity
Variables Univariate analysis Multivariate analysis




Breast volume 0.620 0.692
Diabetes 0.196 0.139
Surgical deficits 0.323 0.890
Boost administration = 0.007174 = 0.0119 [OR 3.056
(1.280 - 7.297)]
V > 100% - 0.642
V > 104% - 0.466
V > 107% - 0.908
Boost V > 100% - 0.981
Boost V > 104% - 0.684
Boost V > 107% - 0.615START B trial, 2215 women with breast cancer were
randomized after breast conserving surgery or mastec-
tomy to standard whole breast irradiation (50 Gy/25 fx)
or accelerated HF-WBI (40 Gy/15 fx) [8]. Both trials
showed similar outcomes with respect to local recur-
rence and adverse cosmesis for patients treated with
hypofractionated regimens compared with standard
treatment. Despite the uniformity of the results, there
are several differences in patient selection, length of
follow-up and use of systemic therapy and radiation
boost among the three trials. In the Canadian study no
patient received boost irradiation and only 10.9% re-
ceived adjuvant systemic therapy. Furthermore, womenFigure 2 Distribution of (A) objective (OCO) and (B) subjective
cosmetic outcome (SCO): (A) excellent cosmeses, (B) good
cosmeses, (C) fair cosmeses and (D) poor cosmeses.
Figure 3 Examples of objective cosmetic results (arms up and arms down): (A) excellent cosmeses, (B) good cosmeses, (C) fair
cosmeses and (D) poor cosmeses.
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in adverse cosmesis observed when such patients were
treated with standard fractionation [21,22]. In contrast,
in the START A and B Trials no exclusion criteria based
on breast size were applied; 36% of patients received ad-
juvant systemic therapy and, although its use was not
standardized, most patients received a radiotherapy
boost. The late toxicity and adverse cosmetic results
were measured and reported differently in these three
trials, as well. The Canadian trial used the Radiation On-
cology Group/European Organization for Research and
Treatment of Cancer (RTOG/EORTC) late scoring
schema for skin and subcutaneous tissues, while the cos-
metic outcome was assessed by a clinical trial nurse at
baseline and 3, 5 and 10 years using the EORTC cos-
metic rating system. All these differences, as emphasized
in a recent review [23], have precluded the widespreadacceptance of hypofractionated approach in United
States, so much so that the American Society of Thera-
peutic Radiology and Oncology (ASTRO) guidelines re-
ported that the HF-WBI was appropriate in patients of
50 years or older at diagnosis, with pathological stage
T1-T2 N0 disease treated with breast conserving sur-
gery, without chemotherapy and with a dose inhomo-
geneity on radiation plan <7%. A consensus on the
applicability of HF-WBI to young patients and those
underwent chemotherapy and/or boost was unable to be
reached, based on the lack of mature clinical data on
these patient subsets.
The most common change in breast appearance after
radiotherapy is shrinkage, edema, retraction and telean-
gectasia. The tissue induration persistent many years
after radiotherapy usually is due to an underlying fibro-
sis, but in the early years the fat necrosis and breast
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effects will appear for as long as patients are alive and
the median follow-up times of the hypofractionated tri-
als varied from 5.1 and 9.7 years. The critical question,
as emphasized by Yarnold and colleagues [24], is
whether the fractionation sensitivity of responses devel-
oping at the time of reporting are representative of those
developing over entire life span of a patient. Curran
et al. showed that cosmesis after breast conserving ther-
apy was worse if patients were followed up much longer
than 5 years [25]. On the contrary, the UK Royal Marsden
Hospital/Gloucestershire Oncology Centre (RMH/GOC)
trial [26] did not show a difference between 5-year and
10-year late adverse. On the basis of these considerations
and uncertainties, nowadays may be unjustified to con-
sider follow-up a factor limiting the interpretation of
current hypofractionation trials [27]. Similarly to what re-
ported in other literature studies, our study showed an
overall low risk of late skin and subcutaneous toxicity in
patients treated with HF-WBI after breast-conserving sur-
gery with a median follow up of 34 months. In the present
study patients with less than 50 years were enrolled. In lit-
erature, some authors used age as a selection criteria [12]
as well as breast size or large chest wall separation. In
addition, the published trials of HF-WBI consisted of
mostly lower-risk patients, therefore the applicability and
safety of hypofractionation in women treated with adju-
vant chemotherapy is not well known. In the past, the
worsening effect of chemotherapy on long-term fibrosis
and cosmetic outcome was reported [28,29]. The impact
of the modern anthracycline- and taxane-based regimens
in patients treated with HF-WBI is unknown. In our study
patients treated with adjuvant chemotherapy (mainly
anthracycline-based) showed a significant increase of late
subcutaneous toxicity (p = 0.0184) and a poor objective
cosmetic outcome (p = 0.0409) at multivariate analysis.
Anyway, the rate of high grade scores remained low.
In regard to the use of a tumor bed boost, the question
“when tumor bed boost is recommended and what is the
optimal method of delivering it with hypofractionated ir-
radiation” is still an unsolved issue. In prospective ran-
domized trials the use of a tumor bed boost after whole
breast irradiation reduced the risk of local recurrence
even in patients with negative margins [30,31]. Besides,
an international survey showed that 85% and 75%
American and European physicians, respectively, would
deliver a boost even with negative margins [32]. The
prospective trials of HF-WBI or never used a boost or
used it at the discretion of the treating physician or de-
partment policy. Recent phase I-II trials investigated the
role of concomitant boost in HF-WBI showing the safety
and short-term efficacy of this approach for early-breast
cancer. Freedman et al. treated 75 women affected by
early-stage breast cancer using intensity modulatedradiation technique (IMRT) with a whole breast dose of
2.25 Gy per day for 20 fractions and with an incorpo-
rated tumor bed boost of 2.8 Gy per fraction for a total
dose of 56 Gy [33]. All breast sizes and chemotherapy
administration were permitted. No excess of acute skin
toxicity was found. Another clinical study of HF-WBI
(40.5 Gy in 15 fractions) and concomitant boost
(+0.5 Gy per day for a total tumor bed dose of 48 Gy)
was carried out on 91 patients with early breast cancer.
The major acute skin toxicity was a reversible grade 1-2
dermatitis occurred in 67% of the patients; there were 2
cases of acute grade 3 toxicities and no late grade 3 ef-
fects. The authors reported a grade 1 and 2 late soft tis-
sue fibrosis in 40% and 3% of patients, respectively [34].
Furthermore, with a median follow-up of 24 months
Chadha et al. reported any significant negative effect of
HF-WBI and concomitant boost on breast cosmesis
[35]. So far, neither the optimal HF-WBI regimen to use
when a boost is planned nor the optimal tumor bed
boost dose fractionation have been determined. In our
study we used the sequential tumor bed boost in pa-
tients ≤50 years or with close margins. A total dose of
9 Gy in three consecutive daily fractions with a non-
coplanar 3D-CRT technique, was delivered. The bed
tumor boost resulted significantly associated with an
higher grade of acute and late skin toxicity (p = 0.05431
and p = 0.0119). Analyzing only the “boost” group, the
multivariate analysis did not show any other clinical fac-
tors related to skin toxicity, as if to signify that the boost
is the main factor involved. As concerns breast volume
as a relevant factor related to skin toxicity contradictory
data are available in the literature. Some authors re-
ported a strict correlation between breast volume size
and severity of acute effects, because large volumes are
frequently associated with dose inhomogeneity and max-
imum doses higher than the 107% of prescribed dose
[36,37]. In addition to acute toxicity, breast volume
seems to increase the risk of late effects, too [37].
On the contrary, Corbin et al. reported that among
obese and large breasted women, in their experience,
there was no increase in acute skin toxicity [38]. One
possible explanation for these discrepancies may be the
different criteria used to define “large breast”. Vicini et
al. [28] found that patients with breast volume > 1600 cc
had more acute skin toxicity than those with smaller
breast. Harsolia showed no grade 3 RTOG acute toxicity
with breast volume <975 cc; patients with breast vol-
umes > 1600 cc developed 59% G2 and 3% G3 RTOG
skin reactions [29]. In this report, as in our study, the
authors measured breast volume manually contouring of
breast target volume. The average breast volume in our
patients were smaller (813.8 cc, range 44.77-1892.1 cc)
than reported in these studies but were substantially
comparable to those recently reported by Tortorelli
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volume and acute skin toxicity at univariate analysis
(p = 0.011) [39]. Our study confirmed a significant
correlation between acute skin toxicity and breast vol-
ume (p = 0.01504). Also, it showed a significant cor-
relation between breast size and objective cosmetic
outcome (p = 0.0207).
In our experience, compliance with this treatment was
excellent thanks to short treatment duration. The overall
objective cosmetic outcome was generally good, with
satisfactory cosmetic results in nearly 90% of patients. A
thorough patients’ judgment of their own cosmetic
outcomes revealed similar findings, and a very low rate
of results rated as “poor”. This was expected as it has
been already reported that patients tend to evaluate the
esthetic outcomes more positively than health care
providers.
As concerns the dosimetric inhomogeneities as a rele-
vant factor related to acute and late toxicity a recent
study suggested that the amount of volume receiving
>107% was correlated with skin reaction [39] as pointed
out by Chen and coll. who demonstrated that larger vol-
ume receiving >53.9 Gy was a significant predictor of ra-
diation induced skin toxicity [40]. The recent UK FAST
trial reported that, after adjusting for breast size and sur-
gical deficits, there was no evidence that the risk of late
adverse effects of HF-WBI was associated with dose in-
homogeneity [41]. Conversely, our results suggest that
dose inhomogeneities (V > 104% and V > 107%) have a
significant impact on the occurrence of severe subcuta-
neous late reaction (p = 0.00864 and p = 0.02045, re-
spectively) but we did not find any correlation between
dosimetric parameters and both acute and late skin tox-
icity. Special focus should be given to dose inhomogen-
eity which do not correlate with skin reaction, because it
may be related to other types of side effects which have
not yet been investigated and reported in the aferomen-
tioned randomized trials, such as late subcutaneous
toxicity.
Conclusions
The results of our study, according to the large random-
ized trials, confirmed that HF-WBI is safe. Our study
showed an increase of late subcutaneous and skin effects
in the patients who received additional boost. Anyway,
the rate of severe toxicity (> grade 2) was low even in
these patients. Then, the number of toxicity events is so
low that no firm conclusion can be drawn from our data
regarding the oncological safety of this procedure in pa-
tients needing of the additional boost.
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